Reviewing in science requires quality criteria and professional reviewers

Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector's contributions to drug development and access

This commentary provides a comprehensive overview of the challenges and opportunities in the field of drug development for rare diseases and especially of gene therapy products for ultra-rare diseases. It discusses the limited market size, reimbursement and scientific complexities that deter pharmaceutical investment in this field. Highlighting the pivotal role of charitable organizations like Fondazione Telethon, it showcases their efforts in funding research and ensuring access to innovative therapies. This commentary also addresses the challenges in therapy distribution, particularly regarding sustainability and global access. It outlines Fondazione Telethon's operational model to try to address these challenges. Finally, it appeals to governments and regulatory bodies to implement policies and incentives aimed at further fostering innovation and accessibility in rare disease drug development and access.

Advancing Self-Evaluative and Self-Regulatory Mechanisms of Scholarly Journals: Editors’ Perspectives on What Needs to Be Improved in the Editorial Process

Meticulous self-evaluative practices in the offices of academic periodicals can be helpful in reducing widespread uncertainty about the quality of scholarly journals. This paper summarizes the results of the second part of a qualitative worldwide study among 258 senior editors of scholarly journals across disciplines. By means of a qualitative questionnaire, the survey investigated respondents’ perceptions of needed changes in their own editorial workflow that could, according to their beliefs, positively affect the quality of their journals. The results show that the most relevant past improvements indicated by respondents were achieved by: (a) raising the required quality criteria for manuscripts, by defining standards for desk rejection and/or shaping the desired qualities of the published material, and (b) guaranteeing a rigorous peer review process. Respondents believed that, currently, three areas have the most pressing need for amendment: ensuring higher overall quality of published articles (26% of respondents qualified this need as very high or high), increasing the overall quality of peer-review reports (23%), and raising reviewers’ awareness of the required quality standards (20%). Bivariate analysis shows that respondents who work with non-commercial publishers reported an overall greater need to improve implemented quality assessment processes. Work overload, inadequate reward systems, and a lack of time for development activities were cited by respondents as the greatest obstacles to implementing necessary amendments.

Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis

The recent approval of Strimvelis, the first ex vivo gene therapy to gain marketing authorization (Schimmer & Breazzano, 2016), has drawn attention to Fondazione Telethon, the Italian charity that played a pivotal role in this effort. Although it is not uncommon that advanced therapies, such as Strimvelis, are developed by partnerships between academia and industry, direct involvement of a charity in key steps of this process is still unusual. Illustrating the strategies and operational model adopted by Fondazione Telethon to achieve its mission of supporting excellent research aimed at curing rare genetic diseases may elucidate some of the enabling factors behind the Strimvelis success story.